{"disease":{"id":"solid-tumor-malignancies","name":"solid tumor malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02457962","title":"Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03486873","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07303387","title":"Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":900,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT04389541","title":"Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT07136779","title":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"VelaVigo Bio Inc","has_results":false},{"nct_id":"NCT04905329","title":"A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations","phase":"","overall_status":"UNKNOWN","enrollment_count":285,"lead_sponsor_name":"Moscow Clinical Scientific Center","has_results":false},{"nct_id":"NCT07195916","title":"A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05315167","title":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":267,"lead_sponsor_name":"Zhuhai Yufan Biotechnologies Co., Ltd","has_results":false},{"nct_id":"NCT07299747","title":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":255,"lead_sponsor_name":"VelaVigo Bio Inc","has_results":false},{"nct_id":"NCT05735275","title":"A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":252,"lead_sponsor_name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07167381","title":"xDRIVE for Florida-based Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"First Ascent Biomedical Inc.","has_results":false},{"nct_id":"NCT07181473","title":"A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Phrontline Biopharma","has_results":false},{"nct_id":"NCT07174453","title":"Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":192,"lead_sponsor_name":"University of Kansas Medical Center","has_results":false},{"nct_id":"NCT05028478","title":"A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":164,"lead_sponsor_name":"Curon Biopharmaceutical (Australia) Co Pty Ltd","has_results":false},{"nct_id":"NCT03082209","title":"A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","has_results":false},{"nct_id":"NCT05690581","title":"Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT02000934","title":"A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":false},{"nct_id":"NCT03739931","title":"Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT06720987","title":"A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Kumquat Biosciences Inc.","has_results":false},{"nct_id":"NCT05023486","title":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":121,"lead_sponsor_name":"Novita Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05306509","title":"Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT06224855","title":"A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Hangzhou DAC Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT01885195","title":"MEK162 for Patients With RAS/RAF/MEK Activated Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07155811","title":"Lymphocyte Function Testing in Immuno-oncology","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT07476534","title":"Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital of Xinxiang Medical College","has_results":false},{"nct_id":"NCT06649708","title":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd.","has_results":false},{"nct_id":"NCT03386526","title":"APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT06136884","title":"A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":86,"lead_sponsor_name":"A2A Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT02160041","title":"BGJ398 for Patients With Tumors With FGFR Genetic Alterations","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":84,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06994806","title":"A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Kumquat Biosciences Inc.","has_results":false},{"nct_id":"NCT02265510","title":"An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":83,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03323398","title":"Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT02298387","title":"A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"OncoMed Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02959437","title":"Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT07363967","title":"A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Beijing StoneWise Technology Co., Ltd","has_results":false},{"nct_id":"NCT04989387","title":"Study of INCA 0186 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT07231120","title":"A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Jiangsu Nutai Biologics Co., Ltd","has_results":false},{"nct_id":"NCT03837899","title":"Durvalumab and Tremelimumab for Pediatric Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06401356","title":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00529438","title":"RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05126433","title":"Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT07475559","title":"JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT05159700","title":"A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":39,"lead_sponsor_name":"Zhuhai Yufan Biotechnologies Co., Ltd","has_results":false},{"nct_id":"NCT07182435","title":"Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","has_results":false},{"nct_id":"NCT07264803","title":"A Single-arm Clinical Trial Using Patient-derived Tumor Tissue Fragment Models for Drug Sensitivity Testing to Guide Treatment in Previously Treated Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT07128914","title":"A Clinical Study of GO306 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"GeneSail Biotech (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT07071090","title":"A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Heronova Pharmaceuticals","has_results":false},{"nct_id":"NCT07325123","title":"Malic Acid Supplementation Combined With Immunotherapy in Patients With Solid Tumors","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Xinxiang Medical College","has_results":false},{"nct_id":"NCT02564198","title":"A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Eli Lilly and Company","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}